Assessment of the Price–Volume Agreement Program in South Korea

Euna Han, Sun Young Park, Eui Kyung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Price–Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003–2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03% higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.

Original languageEnglish
Pages (from-to)1209-1215
Number of pages7
JournalHealth Policy
Volume120
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Republic of Korea
Health Expenditures
Pharmaceutical Preparations
National Health Programs
Linear Models
Drug and Narcotic Control
Negotiating

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Han, Euna ; Park, Sun Young ; Lee, Eui Kyung. / Assessment of the Price–Volume Agreement Program in South Korea. In: Health Policy. 2016 ; Vol. 120, No. 10. pp. 1209-1215.
@article{798030acf29042b9b5220547993c68e1,
title = "Assessment of the Price–Volume Agreement Program in South Korea",
abstract = "The Price–Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003–2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03{\%} higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.",
author = "Euna Han and Park, {Sun Young} and Lee, {Eui Kyung}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.healthpol.2016.07.017",
language = "English",
volume = "120",
pages = "1209--1215",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "10",

}

Assessment of the Price–Volume Agreement Program in South Korea. / Han, Euna; Park, Sun Young; Lee, Eui Kyung.

In: Health Policy, Vol. 120, No. 10, 01.10.2016, p. 1209-1215.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of the Price–Volume Agreement Program in South Korea

AU - Han, Euna

AU - Park, Sun Young

AU - Lee, Eui Kyung

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The Price–Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003–2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03% higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.

AB - The Price–Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003–2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03% higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.

UR - http://www.scopus.com/inward/record.url?scp=84994252994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994252994&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2016.07.017

DO - 10.1016/j.healthpol.2016.07.017

M3 - Article

VL - 120

SP - 1209

EP - 1215

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 10

ER -